OptiBiotix Health PLC Director Appointment (7784Q)
02 March 2021 - 6:00PM
UK Regulatory
TIDMOPTI
RNS Number : 7784Q
OptiBiotix Health PLC
02 March 2021
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Director Appointment
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, a nn o unces that further to the
announcement made on 2 February 2021 regarding the intention to
appoint Stephen Hammond MP as a Director of the Company, the
regulatory due diligence process required for a Board position has
been completed, and Stephen will join the Board as a Non-Executive
Director with immediate effect. The text below sets out the
required disclosures.
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies, the following information is disclosed in respect of
Stephen William Hammond (aged 59):
Current Appointments Appointments in the last five years
Harwood Film Partnership Commonwealth Parliamentary Association (United
LLP Kingdom Branch)
-----------------------------------------------
Peal Gas LLC G-Volution Limited
-----------------------------------------------
South Coast Regeneration & Investment Property
Co Limited
-----------------------------------------------
In December 2020 The Office of the Advisory Committee on
Business Appointments noted that whilst Stephen Hammond had
complied with the House of Commons regulatory disclosure
requirements, he did not seek advice as he was required to do in
relation to his role at Public Policy Projects, a think tank policy
institute, and as a consequence had breached Government's Rules and
the requirement set out in the Ministerial Code.
Stephen Hammond MP does not currently own any shares or options
in the Company.
There is no further information regarding Stephen Hammond MP
required to be disclosed under the AIM Rules.
Neil Davidson, Chairman of OptiBiotix commented: "We are pleased
to confirm the appointment of Stephen Hammond which reflects the
continued development of the Company and the ambition of the Board
to build a profitable international business with global
brands.
"The Company anticipate that there will be further additions and
changes to the Board and management teams as it continues to grow
sales, expand into international markets and commercialises its
next generation products."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the
content of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
Stephen O'Hara, Chief Executive below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI) is a biotechnology company
formed in March 2012 which, brings science and human stuidies to
the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to
prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than seventy international food and
healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a
wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUPUQWWUPGPUG
(END) Dow Jones Newswires
March 02, 2021 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024